Evaluation of agreement rates between radionuclide bone scintigraphy and radioimmunoscintigraphy with indium-111-capromab pendetide (Prostascint) in patients with rising PSA after definitive prostate cancer treatment

被引：0
|
作者：
Thomas, CT
Montie, JE
Sandler, HS
Zasadny, KR
Wahl, RL
机构：
来源：
RADIOLOGY | 2000年 / 217卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1498
引用
收藏
页码：568 / 569
页数：2
相关论文
共 13 条
  • [1] Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
    Manyak, MJ
    Hinkle, GH
    Olsen, JO
    Chiaccherini, RP
    Partin, AW
    Piantadosi, S
    Burgers, JK
    Texter, JH
    Neal, CE
    Libertino, JA
    Wright, GL
    Maguire, RT
    UROLOGY, 1999, 54 (06) : 1058 - 1063
  • [2] IMAGE-GUIDED RADIOTHERAPY FOR PROSTATE CANCER: A PROSPECTIVE TRIAL OF CONCOMITANT BOOST USING INDIUM-111-CAPROMAB PENDETIDE (PROSTASCINT) IMAGING
    Wong, William W.
    Schild, Steven E.
    Vora, Sujay A.
    Ezzell, Gary A.
    Nguyen, Ba D.
    Ram, Panol C.
    Roarke, Michael C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (04): : E423 - E429
  • [3] Indium-111 Capromab Pendetide (ProstaScint) falls to reliably detect metastases in patients before and after treatment for localized prostate cancer
    Seltzer, M
    Barbaric, Z
    Naitoh, J
    Cangiano, T
    deKernion, J
    Belldegrun, A
    Phelps, M
    Hoh, C
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 150P - 150P
  • [4] Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer
    Haseman, Michael K.
    Rosenthal, Seth A.
    Kipper, Samuel L.
    Trout, J. Richard
    Manyak, Michael J.
    UROLOGY, 2007, 70 (02) : 303 - 308
  • [5] 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy
    Kahn, D
    Williams, RD
    Manyak, MJ
    Haseman, MK
    Seldin, DW
    Libertino, JA
    Maguire, RT
    JOURNAL OF UROLOGY, 1998, 159 (06): : 2041 - 2046
  • [6] 111indium-capromab pendetide in evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy -: Comment
    Seltzer, M
    Naitoh, J
    JOURNAL OF UROLOGY, 1998, 159 (06): : 2046 - 2046
  • [7] 111indium-capromab pendetide in evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy -: Comment -: Reply
    不详
    JOURNAL OF UROLOGY, 1998, 159 (06): : 2047 - 2047
  • [8] Serial indium-111 capromab pendetide (Prostascint) imaging in patients with recurrent or locally advanced prostate cancer (LAPC) undergoing combined modality therapies
    Sarikaya, I
    Hussain, A
    Bacetti, N
    Siegel, E
    Holder, L
    Line, B
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (08): : 1213 - 1213
  • [9] Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer
    Nagda, Suneel N.
    Morideen, Najeeb
    Lo, Simon S.
    Khan, Usman
    Dillehay, Gary
    Wagner, Robert
    Campbell, Steven
    Flanigan, Robert
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (03): : 834 - 840
  • [10] Prospective evaluation of atorvastatin in patients with PSA relapse after definitive treatment for prostate cancer
    Nawaz, U.
    Charles, J. B.
    Hajdenberg, A. V.
    Cohen, N.
    Hajdenberg, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12